Literature DB >> 27625789

Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers.

Ji-Hyun Lee1, Xing-Ming Zhao2, Ina Yoon3, Jin Young Lee3, Nam Hoon Kwon3, Yin-Ying Wang2, Kyung-Min Lee4, Min-Joo Lee4, Jisun Kim4, Hyeong-Gon Moon4, Yongho In3, Jin-Kao Hao5, Kyung-Mii Park6, Dong-Young Noh4, Wonshik Han7, Sunghoon Kim8.   

Abstract

Despite the explosion in the numbers of cancer genomic studies, metastasis is still the major cause of cancer mortality. In breast cancer, approximately one-fifth of metastatic patients survive 5 years. Therefore, detecting the patients at a high risk of developing distant metastasis at first diagnosis is critical for effective treatment strategy. We hereby present a novel systems biology approach to identify driver mutations escalating the risk of metastasis based on both exome and RNA sequencing of our collected 78 normal-paired breast cancers. Unlike driver mutations occurring commonly in cancers as reported in the literature, the mutations detected here are relatively rare mutations occurring in less than half metastatic samples. By supposing that the driver mutations should affect the metastasis gene signatures, we develop a novel computational pipeline to identify the driver mutations that affect transcription factors regulating metastasis gene signatures. We identify driver mutations in ADPGK, NUP93, PCGF6, PKP2 and SLC22A5, which are verified to enhance cancer cell migration and prompt metastasis with in vitro experiments. The discovered somatic mutations may be helpful for identifying patients who are likely to develop distant metastasis.

Entities:  

Keywords:  RNA sequencing; driver mutations; exome sequencing; integrative analysis; metastatic breast cancer

Year:  2016        PMID: 27625789      PMCID: PMC5004232          DOI: 10.1038/celldisc.2016.25

Source DB:  PubMed          Journal:  Cell Discov        ISSN: 2056-5968            Impact factor:   10.849


  67 in total

Review 1.  TGF-beta and epithelial-to-mesenchymal transitions.

Authors:  Jiri Zavadil; Erwin P Böttinger
Journal:  Oncogene       Date:  2005-08-29       Impact factor: 9.867

Review 2.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

3.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

4.  Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.

Authors:  Bin Guan; Min Gao; Chen-Hsuan Wu; Tian-Li Wang; Ie-Ming Shih
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

5.  The localisation and reduction of nuclear staining of PPARgamma and PGC-1 in human breast cancer.

Authors:  Gareth Watkins; Anthony Douglas-Jones; Robert E Mansel; Wen G Jiang
Journal:  Oncol Rep       Date:  2004-08       Impact factor: 3.906

6.  PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro.

Authors:  H Liu; C Zang; M H Fenner; K Possinger; E Elstner
Journal:  Breast Cancer Res Treat       Date:  2003-05       Impact factor: 4.872

7.  The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics.

Authors:  P Vlachos; B Joseph
Journal:  Oncogene       Date:  2009-09-07       Impact factor: 9.867

8.  Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.

Authors:  Siân Jones; Meng Li; D Williams Parsons; Xiaosong Zhang; Jelle Wesseling; Petra Kristel; Marjanka K Schmidt; Sanford Markowitz; Hai Yan; Darell Bigner; Ralph H Hruban; James R Eshleman; Christine A Iacobuzio-Donahue; Michael Goggins; Anirban Maitra; Sami N Malek; Steve Powell; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Hum Mutat       Date:  2011-11-23       Impact factor: 4.878

9.  Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.

Authors:  Jens G Lohr; Viktor A Adalsteinsson; Kristian Cibulskis; Atish D Choudhury; Mara Rosenberg; Peter Cruz-Gordillo; Joshua M Francis; Cheng-Zhong Zhang; Alex K Shalek; Rahul Satija; John J Trombetta; Diana Lu; Naren Tallapragada; Narmin Tahirova; Sora Kim; Brendan Blumenstiel; Carrie Sougnez; Alarice Lowe; Bang Wong; Daniel Auclair; Eliezer M Van Allen; Mari Nakabayashi; Rosina T Lis; Gwo-Shu M Lee; Tiantian Li; Matthew S Chabot; Amy Ly; Mary-Ellen Taplin; Thomas E Clancy; Massimo Loda; Aviv Regev; Matthew Meyerson; William C Hahn; Philip W Kantoff; Todd R Golub; Gad Getz; Jesse S Boehm; J Christopher Love
Journal:  Nat Biotechnol       Date:  2014-04-20       Impact factor: 54.908

10.  Genome-wide analysis of noncoding regulatory mutations in cancer.

Authors:  Nils Weinhold; Anders Jacobsen; Nikolaus Schultz; Chris Sander; William Lee
Journal:  Nat Genet       Date:  2014-09-28       Impact factor: 38.330

View more
  31 in total

1.  Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent.

Authors:  Yaohua Yang; Lang Wu; Xiao-Ou Shu; Qiuyin Cai; Xiang Shu; Bingshan Li; Xingyi Guo; Fei Ye; Kyriaki Michailidou; Manjeet K Bolla; Qin Wang; Joe Dennis; Irene L Andrulis; Hermann Brenner; Georgia Chenevix-Trench; Daniele Campa; Jose E Castelao; Manuela Gago-Dominguez; Thilo Dörk; Antoinette Hollestelle; Artitaya Lophatananon; Kenneth Muir; Susan L Neuhausen; Håkan Olsson; Dale P Sandler; Jacques Simard; Peter Kraft; Paul D P Pharoah; Douglas F Easton; Wei Zheng; Jirong Long
Journal:  J Natl Cancer Inst       Date:  2020-03-01       Impact factor: 13.506

2.  Targeted next-generation sequencing in papillary thyroid carcinoma patients looking for germline variants predisposing to the disease.

Authors:  Chen-Tian Shen; Guo-Qiang Zhang; Zhong-Ling Qiu; Hong-Jun Song; Zhen-Kui Sun; Quan-Yong Luo
Journal:  Endocrine       Date:  2019-03-02       Impact factor: 3.633

3.  Cancer classification and pathway discovery using non-negative matrix factorization.

Authors:  Zexian Zeng; Andy H Vo; Chengsheng Mao; Susan E Clare; Seema A Khan; Yuan Luo
Journal:  J Biomed Inform       Date:  2019-07-02       Impact factor: 6.317

4.  Nucleoporin-93 reveals a common feature of aggressive breast cancers: robust nucleocytoplasmic transport of transcription factors.

Authors:  Nishanth Belugali Nataraj; Ashish Noronha; Joo Sang Lee; Soma Ghosh; Harsha Raj Mohan Raju; Arunachalam Sekar; Binyamin Zuckerman; Moshit Lindzen; Emilio Tarcitano; Swati Srivastava; Michael Selitrennik; Ido Livneh; Diana Drago-Garcia; Oscar Rueda; Carlos Caldas; Sima Lev; Tamar Geiger; Aaron Ciechanover; Igor Ulitsky; Rony Seger; Eytan Ruppin; Yosef Yarden
Journal:  Cell Rep       Date:  2022-02-22       Impact factor: 9.423

5.  Sleep and Late-Onset Alzheimer's Disease: Shared Genetic Risk Factors, Drug Targets, Molecular Mechanisms, and Causal Effects.

Authors:  Dongze Chen; Xinpei Wang; Tao Huang; Jinzhu Jia
Journal:  Front Genet       Date:  2022-05-17       Impact factor: 4.772

6.  Integrative 3' Untranslated Region-Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple-Negative Breast Cancer.

Authors:  Lei Wang; Xin Hu; Peng Wang; Zhi-Ming Shao
Journal:  Oncologist       Date:  2018-08-06

7.  The node-weighted Steiner tree approach to identify elements of cancer-related signaling pathways.

Authors:  Yahui Sun; Chenkai Ma; Saman Halgamuge
Journal:  BMC Bioinformatics       Date:  2017-12-28       Impact factor: 3.169

8.  Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study.

Authors:  Yin-Ying Wang; Hong Bai; Run-Zhi Zhang; Hong Yan; Kang Ning; Xing-Ming Zhao
Journal:  Oncotarget       Date:  2017-09-30

9.  The lncRNA BORG Drives Breast Cancer Metastasis and Disease Recurrence.

Authors:  Alex J Gooding; Bing Zhang; Fereshteh Kenari Jahanbani; Hannah L Gilmore; Jenny C Chang; Saba Valadkhan; William P Schiemann
Journal:  Sci Rep       Date:  2017-10-05       Impact factor: 4.379

Review 10.  Roles for growth factors and mutations in metastatic dissemination.

Authors:  Nishanth Belugali Nataraj; Ilaria Marrocco; Yosef Yarden
Journal:  Biochem Soc Trans       Date:  2021-06-30       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.